Robin Park1, Sul A Lee1, Seong Yoon Kim1, Andreia Cristina de Melo2, Anup Kasi3. 1. Department of Medicine, MetroWest Medical Center/Tufts University School of Medicine, Framingham, MA, USA. 2. Divisão de Pesquisa Clínica e Desenvolvimento Tecnológico, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil. 3. Department of Medicine, Division of Medical Oncology, Kansas University Cancer Center, Kansas, MO, USA.
Abstract
BACKGROUND: Cancer patients suffer from worse coronavirus disease-2019 (COVID-19) outcomes. Whether active oncologic treatment is an additional risk factor in this population remains unclear. Therefore, here we have conducted a systematic review and meta-analysis to summarize the existing evidence for the effect of active oncologic treatment on COVID-19 outcomes. METHODS: Systematic search of databases (PubMed, Embase) was conducted for studies published from inception to July 1, 2020, with a subsequent search update conducted on 10 October 2020. In addition, abstracts and presentations from major conference proceedings (ASCO, ESMO, AACR) as well as pre-print databases (medxriv, bioxriv) were searched. Retrospective and prospective studies reporting clinical outcomes in cancer patients with laboratory confirmation or clinical diagnosis of COVID-19 and details of active or recent oncologic treatment were selected. Random-effects model was applied throughout meta-analyses. Summary outcome measure was the pooled odds ratio (OR) of death for active cancer therapy versus no active cancer therapy for each of the following modalities: recent surgery, chemotherapy, targeted therapy, immunotherapy, or chemoimmunotherapy. RESULTS: Sixteen retrospective and prospective studies (3558 patients) were included in the meta-analysis. Active chemotherapy was associated with higher risk of death compared to no active chemotherapy (OR, 1.60, 95% CI, 1.14-2.23). No significant association with risk of death was identified for active targeted therapy, immunotherapy, chemoimmunotherapy, or recent surgery. Meta-analysis of multivariate adjusted OR of death for active chemotherapy was consistently associated with higher risk of death compared to no active chemotherapy (OR, 1.42, 95% CI, 1.01-2.01). CONCLUSIONS: Active chemotherapy appears to be associated with higher risk of death in cancer patients with COVID-19. Further research is necessary to characterize the complex interactions between active cancer treatment and COVID-19.
BACKGROUND:Cancerpatients suffer from worse coronavirus disease-2019 (COVID-19) outcomes. Whether active oncologic treatment is an additional risk factor in this population remains unclear. Therefore, here we have conducted a systematic review and meta-analysis to summarize the existing evidence for the effect of active oncologic treatment on COVID-19 outcomes. METHODS: Systematic search of databases (PubMed, Embase) was conducted for studies published from inception to July 1, 2020, with a subsequent search update conducted on 10 October 2020. In addition, abstracts and presentations from major conference proceedings (ASCO, ESMO, AACR) as well as pre-print databases (medxriv, bioxriv) were searched. Retrospective and prospective studies reporting clinical outcomes in cancerpatients with laboratory confirmation or clinical diagnosis of COVID-19 and details of active or recent oncologic treatment were selected. Random-effects model was applied throughout meta-analyses. Summary outcome measure was the pooled odds ratio (OR) of death for active cancer therapy versus no active cancer therapy for each of the following modalities: recent surgery, chemotherapy, targeted therapy, immunotherapy, or chemoimmunotherapy. RESULTS: Sixteen retrospective and prospective studies (3558 patients) were included in the meta-analysis. Active chemotherapy was associated with higher risk of death compared to no active chemotherapy (OR, 1.60, 95% CI, 1.14-2.23). No significant association with risk of death was identified for active targeted therapy, immunotherapy, chemoimmunotherapy, or recent surgery. Meta-analysis of multivariate adjusted OR of death for active chemotherapy was consistently associated with higher risk of death compared to no active chemotherapy (OR, 1.42, 95% CI, 1.01-2.01). CONCLUSIONS: Active chemotherapy appears to be associated with higher risk of death in cancerpatients with COVID-19. Further research is necessary to characterize the complex interactions between active cancer treatment and COVID-19.
Authors: Marina Treskova-Schwarzbach; Laura Haas; Sarah Reda; Antonia Pilic; Anna Borodova; Kasra Karimi; Judith Koch; Teresa Nygren; Stefan Scholz; Viktoria Schönfeld; Sabine Vygen-Bonnet; Ole Wichmann; Thomas Harder Journal: BMC Med Date: 2021-08-27 Impact factor: 8.775
Authors: Eusebi Chiner-Vives; Rosa Cordovilla-Pérez; David de la Rosa-Carrillo; Marta García-Clemente; José Luis Izquierdo-Alonso; Remedios Otero-Candelera; Luis Pérez-de Llano; Jacobo Sellares-Torres; José Ignacio de Granda-Orive Journal: Arch Bronconeumol Date: 2022-04-15 Impact factor: 6.333
Authors: Egidio Imbalzano; Luana Orlando; Angela Sciacqua; Giuseppe Nato; Francesco Dentali; Veronica Nassisi; Vincenzo Russo; Giuseppe Camporese; Gianluca Bagnato; Arrigo F G Cicero; Giuseppe Dattilo; Marco Vatrano; Antonio Giovanni Versace; Giovanni Squadrito; Pierpaolo Di Micco Journal: J Clin Med Date: 2021-12-31 Impact factor: 4.241
Authors: Elena Roel; Andrea Pistillo; Martina Recalde; Sergio Fernández-Bertolín; María Aragón; Isabelle Soerjomataram; Mazda Jenab; Diana Puente; Daniel Prieto-Alhambra; Edward Burn; Talita Duarte-Salles Journal: Int J Cancer Date: 2021-11-03 Impact factor: 7.316
Authors: Ottavia Zattra; Anthony Fraga; Nancy Lu; Michael S Gee; Raymond W Liu; Michael H Lev; James A Brink; Sanjay Saini; Min Lang; Marc D Succi Journal: Cancer Med Date: 2021-08-06 Impact factor: 4.711